Cetuximab patent?

See the DrugPatentWatch profile for Cetuximab

What is Cetuximab and How Does its Patent Affect the Market?

Cetuximab is a monoclonal antibody drug used to treat various types of cancer, including colorectal, head and neck, and skin cancer. It works by blocking the epidermal growth factor receptor (EGFR), inhibiting cancer cell growth and proliferation [1].

Who Owns the Patent and When Does it Expire?

The patent for Cetuximab, also known as Erbitux, is owned by Eli Lilly and Company, and it has been licensed to Merck KGaA and Pfizer. The original patent for Cetuximab expired in 2019, but the companies involved have entered into patent settlements and extensions to maintain exclusivity [2].

Impact of Patent Expiration on the Market

The expiration of the Cetuximab patent has led to increased competition in the market for EGFR inhibitors. Several biosimilars, such as Targovax's TGTX-110 and Spectrum Pharmaceuticals' Zarxio, have been approved and are expected to enter the market soon. Biosimilars are highly similar versions of the original biologic medication, but they are not identical and may have minor differences in formulation or manufacturing [3].

Challenges to Patent Exclusivity

Despite the patent expiration, companies like Merck KGaA and Pfizer have taken steps to maintain exclusivity and protect their market share. They have filed lawsuits against generic drugmakers, including Teva Pharmaceuticals, alleging patent infringement and interference with their market exclusivity [4].

What Does this Mean for Patients and Healthcare Providers?

The entry of biosimilars into the market for Cetuximab may provide patients with more affordable treatment options. However, it may also lead to delays in access to the medication, as manufacturers and distributors work to meet demand and ensure that the biosimilars are safe and effective for use [5].

Sources:
[1] National Cancer Institute. (2022). Cetuximab. Retrieved from https://www.cancer.gov/about-cancer/treatment/drugs/cetuximab
[2] Merck KGaA. (2020). Press Release: Merck KGaA, Darmstadt, Germany Announces Patent Extension for Cetuximab.
[3] FDA. (2020). Approvals & Applications.
[4] Bloomberg Law. (2020). Merck Sues Teva Over Cetuximab Patent Challenge.
[5] American Cancer Society. (2022). Cetuximab: What you need to know.